Sterling Pharma Solutions
Christopher Creighton is an accomplished professional in the pharmaceutical field, currently serving as Senior Director of Process Chemistry and API Manufacture at Sterling Pharma Solutions since August 2023. As an Independent Consultant for Isotide since January 2022, Christopher leverages extensive industry experience that includes roles as General Partner at Intelibis Research from July 2018 to December 2021, Director of Research and Development and later Associate Director of Chemistry at Hamari, USA from 2011 to July 2018, and Principal Scientist at Trius Therapeutics from 2006 to 2010. Prior experience includes a Senior Scientist role at Johnson & Johnson Pharmaceutical Research & Development from 2000 to 2006, and a foundational education with a Ph.D. in Organic Chemistry and a B.S. in Chemistry from the University of California at San Diego, completed between 1995 and 2000 and 1990 and 1995, respectively.
This person is not in any teams
This person is not in any offices
Sterling Pharma Solutions
1 followers
Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry. Our facilities are located in Cramlington and Newcastle Biosphere, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Our state-of-the-art facilities, proprietary technologies and experienced people are among the best in the industry. We have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle, from grams to tonnes, from pre-clinical to commercial supply. Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and CIA Gold Awards for Safety the last three consecutive years. We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to our customers. In addition, our North Carolina and Newcastle Biosphere facilities offer expert chemistry solutions for small volume batches or products in the early stages of clinical trials. Our Deeside, Wales facility provide bioconjugation development services and specialised in antibody drug conjugation (ADC) research and development. Find out more: www.sterlingpharmasolutions.com/sterling-facilities